SCHEMBL21592279

SCHEMBL21592279

Cc1oc2ccccc2c(=O)c1CN(CCCc1cccnc1)Cc1ccncc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 9/20 0.44
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HDAC9 Q9UKV0 1/20 0.43
▸ HDAC5 Q9UQL6 1/20 0.43
▸ VKORC1 Q9BQB6 1/20 0.41
▸ KCNJ5 P48544 4/20 0.41
▸ KCNJ3 P48549 4/20 0.41
▸ HSD17B10 Q99714 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ IGLV6-57 P01721 3/20 0.37
▸ BCHE P06276 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591552 0.88 KCNA5 (0.41) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21591500 0.84 HDAC3 (0.41) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL31361801 0.84 HDAC3 (0.41) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21591460 0.84 KCNA5 (0.40) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL24763274 0.83 KCNA5 (0.39) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21591520 0.82 HDAC3 (0.41) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21591463 0.80 CYP11B1 (0.54) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21592272 0.79 NPC1 (0.48) HSD17B10L3MBTL1
SCHEMBL21592245 0.79 KCNA5 (0.38) KCNA5HDAC3HDAC4HDAC1HDAC7
SCHEMBL21591555 0.79 KCNA5 (0.40) KCNA5HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS KCNA5 2592/4885HDAC3 4804/4885HDAC4 4173/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS KCNA5 2592/4885HDAC3 4804/4885HDAC4 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback